• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Copley Scientific banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Medivir to market Adasuve inhaled loxapine in Nordic countries

Medivir AB has entered into a license agreement with Ferrer for exclusive rights to commercialize Adasuve inhaled loxapine in Denmark, Finland, Norway, Iceland and Sweden. The company is paying Ferrer an undisclosed amount up front, plus sales-based milestone payments.

Medivir CEO Maris Hartmanis commented, “This licensing agreement is in line with our strategy to add new products to our Nordic portfolio. Adasuve is the first addition to the portfolio, which now consists of 16 prescription pharmaceuticals. Adasuve is a very interesting product based on a novel administration technology addressing an unmet medical need, which expands our present offering to psychiatrists, Lithionit. We are excited about having secured the commercial rights to Adasuve for the Nordic region and the partnership with Ferrer”.

Ferrer COO Antoni Villaró added, “We believe that Adasuve will be a breakthrough in the treatment of agitation and is going to change the way in which the condition is viewed by both healthcare professionals and patients. We are excited to be introducing Adasuve to the European psychiatric and hospital treatment community as Adasuve is now available in Germany, and thank to this agreement soon in the Nordic countries.”

Adasuve loxapine inhalation powder was developed by Alexza for the treatment of agitation in schizophrenia patients. Ferrer acquired the rights to commercialize Adasuve in Europe, Commonwealth of Independent States countries, and Latin America in 2011. Teva obtained US rights to Adasuve in May 2013.

Read the Medivir press release.

Share

published on September 18, 2013

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews